COMPANY

MandalMed, Inc.

HQ: San Francisco, CA source · mandalmed.com ↗ · West Coast

Keywords: myocardial infarction heart failure

Location: San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

23NIH grants

NIH awards 23

Annual award amounts. Total $6.3M.

Jul 23, 2024 NIH award 1R43AR084638-01 FY2024: $306,872 awarded for that fiscal year; activity R43 (SBIR); PI MOUNZIH, KHALID; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Cell-based Gene Therapy for MPS IVA source ↗
Sep 20, 2018 NIH award 1R43DK107285-01A1 FY2018: $299,900 awarded for that fiscal year; activity R43 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Biologic Inhibitor of Galectin-3 for Liv source ↗
Aug 17, 2018 NIH award 3R44AG054386-03S1 FY2018: $131,530 awarded for that fiscal year; activity R44 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Inhibition of Galectin-3 for Therapy of source ↗
Mar 6, 2018 NIH award 5R44AG054386-03 FY2018: $1,061,083 awarded for that fiscal year; activity R44 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Inhibition of Galectin-3 for Therapy of source ↗
Apr 10, 2017 NIH award 4R44AG054386-02 FY2017: $808,592 awarded for that fiscal year; activity R44 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Inhibition of Galectin-3 for Therapy of Re source ↗
Aug 15, 2016 NIH award 1R44AG054386-01A1 FY2016: $224,734 awarded for that fiscal year; activity R44 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Inhibition of Galectin-3 for Therapy of source ↗
Aug 26, 2013 NIH award 1R43HL120645-01 FY2013: $299,958 awarded for that fiscal year; activity R43 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Protein inhibitor of galectin-3 to limit f source ↗
Aug 21, 2011 NIH award 1R43ES019824-01A1 FY2011: $250,000 awarded for that fiscal year; activity R43 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Model of the Human Testis for Reproducti source ↗
Sep 15, 2008 NIH award 1R43CA135862-01A1 FY2008: $363,936 awarded for that fiscal year; activity R43 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Preclinical Testing of Galectin-3C for M source ↗
Aug 10, 2007 NIH award 1R43HD056620-01 FY2007: $255,200 awarded for that fiscal year; activity R43 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Human Sertoli Cell Model for Study of Male source ↗
Jan 28, 2005 NIH award 1R43DK069128-01 FY2005: $134,000 awarded for that fiscal year; activity R43 (SBIR); PI REYNOLDS, ELWOOD E.; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. NO-donor/SOD-mimetics for diabetic nephr source ↗
Jun 30, 2004 NIH award 5R44HD042333-03 FY2004: $375,427 awarded for that fiscal year; activity R44 (SBIR); PI TRIVEDI, ALPA A; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Novel Ex Vivo Gene Therapy for Spinal Cord I source ↗
Aug 7, 2003 NIH award 2R44HD042333-02 FY2003: $374,553 awarded for that fiscal year; activity R44 (SBIR); PI TRIVEDI, ALPA A; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Novel Ex Vivo Gene Therapy for Spinal Cord I source ↗
Jun 1, 2002 NIH award 5R43CA092801-02 FY2002: $255,495 awarded for that fiscal year; activity R43 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Novel Treatment for Breast Cancer: Truncat source ↗
Mar 29, 2002 NIH award 1R43HD042333-01 FY2002: $155,695 awarded for that fiscal year; activity R43 (SBIR); PI TRIVEDI, ALPA A; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Novel Ex Vivo Gene Therapy for Spinal Cord I source ↗
Jul 10, 2001 NIH award 1R43CA092801-01 FY2001: $236,893 awarded for that fiscal year; activity R43 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. Novel Treatment for Breast Cancer: Truncat source ↗
Sep 26, 2000 NIH award 3R43DK057356-01S1 FY2000: $49,287 awarded for that fiscal year; activity R43 (SBIR); PI JOHN, CONSTANCE M; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. PLACENTAL CELLS FOR PROTECTION OF IMPLANT source ↗
Jul 17, 2000 NIH award 1R43DK057356-01 FY2000: $142,130 awarded for that fiscal year; activity R43 (SBIR); PI HALL, DEBORAH E; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. CELLS FOR PROTECTION OF IMPLANTED B ISLETS source ↗
Sep 9, 1999 NIH award 1R41HD037351-01 FY1999: $125,000 awarded for that fiscal year; activity R41 (STTR); PI HALL, DEBORAH E; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. THERAPY OF SPINAL CORD INJURY WITH NEUROTROP source ↗
Jun 9, 1999 NIH award 1R43NS038814-01 FY1999: $135,801 awarded for that fiscal year; activity R43 (SBIR); PI HALL, DEBORAH E; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. GALECTIN 1 FOR MULTIPLE SCLEROSIS source ↗
Mar 14, 1998 NIH award 1R41DK053585-01 FY1998: $99,862 awarded for that fiscal year; activity R41 (STTR); PI MOUNTZ, JOHN D; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. FAST LIGAND FOR PROTECTION OF TRANSPLANTED B I source ↗
Sep 30, 1996 NIH award 1R43AI039306-01 FY1996: $99,420 awarded for that fiscal year; activity R43 (SBIR); PI PAN, GEORGE; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. NOVEL INHIBITORS OF T CELL APOPTOSIS FOR AIDS source ↗
Sep 30, 1996 NIH award 1R41AI038612-01A1 FY1996: $94,294 awarded for that fiscal year; activity R41 (STTR); PI MCDONALD, JAY M.; recipient as written: MANDALMED, INC., SAN FRANCISCO, CA. INHIBITION OF APOPTOSIS IN HIV 1 BY NOVEL source ↗